Impax Laboratories (IPXL) Announes FDA Approval For Generic Precose
More News related to IPXL
- Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
- Impax Laboratories (IPXL) Initiates Challenges to Abbott's Patents in Connection to TRICOR
- Impax Laboratories Confirms Patent Challenge Relating to TRICOR(R) 48mg and 145mg Tablets
- Impax Laboratories (IPXL) Initiates Phase III Trial of IPX066 in Parkinson's
More News related to FDA
- S&P Announces Change to US Index: LL for UCBH
- Electronic Arts (ERTS) Makes Major Job Cuts As Q2 Profits Lag
- Kraft (KFT) to Ask Holders to Vote to Issue New Shares
- Sprint Nextel (S) Aims to Reduce Labor Costs by $350M in Q409
- Highlights From DISH's Q3 Conference Call - Q&A Session
Impax Laboratories, Inc. (NASDAQ: IPXL) confirmed that the FDA has granted approval of the Company’s Abbreviated New Drug Application for generic versions of Precose Tablets (acarbose), 25 mg, 50 mg and 100 mg strengths.
Precose, a Bayer HealthCare Pharmaceuticals product, is used in the management of type two diabetes mellitus.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
